30 closest matches · ranked by relevance
Carcinomatous Edema
Primary: Change in Body Weight From Baseline at Final IMP Administration — -0.69; -0.34; -1.13; 0.70 Kg
Esophageal Neoplasm
Primary: Pulmonary Gas Exchange During and After Esophageal Carcinoma Surgery (PaO2/FiO2 Ratio) — 345.01; 330.11; 315.51; 307.11 mmHg — p=0.410
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Stage IV Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: Percentage of Participants With Reduction in Grade 3/4 Neutropenia — 40; 13 percentage of participants
Non-small Cell Lung Cancer · Mesothelioma · Lung Neoplasms
Primary: Overview of Adverse Events — 28; 23; 12; 1 participants
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Peritoneal Neoplasms · Ascites · Yang Deficiency
Primary: Objective Response Rate (ORR) — 77.7; 63.8 percentage of participants — p=0.0140
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Extensive-Stage Small Cell Lung Cancer
Primary: 1-year Survival — 38 percentage of participants
Neoplasm, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 12.6 months
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Malignant Ascites
Primary: The Proportion of Patients Who Achieved at Least a 4-fold Increase of Puncture/Paracentesis-free Interval Following Catumaxomab Relative to Their Pre-treatment Interval…
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 3; 0 Participants
Non Small Cell Lung Cancer
Primary: Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response) — 28.6 percentage of participants
Esophageal Squamous Cell Carcinoma
Primary: Complete Pathologic Response Rate — 6 Participants
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Secondary Lymphedema
Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale
Peritoneal Carcinomatosis
Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Lung Cancer
Primary: Number of Participants Whose Response Allowed Them to Proceed to Chemoradiation — 38 participants
Carcinoma, Non-Small-Cell Lung
Primary: Number of Subjects With Major Pathologic Response (MPR) — 17 Participants
Pancreatic Cancer
Primary: Effects of PEGPH20